Subcutaneous bortezomib combined with weekly cyclophosphamide and dexamethasone is an efficient and well tolerated regime in newly diagnosed multiple myeloma.
Ong SY et al. Br J Haematol. 2014 Nov 21. doi: 10.1111/bjh.13238. [Epub ahead of print].
Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients.
Clark RE et al. Blood Cancer J. 2014 Oct 31;4:e255. doi: 10.1038/bcj.2014.79.
Phase 2 study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.
Rodon P et al. Haematologica. 2014 Nov 14. pii: haematol.2014.110890. [Epub ahead of print].
Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone.
Morgan G et al. Br J Haematol. 2014 Nov 18. doi: 10.1111/bjh.13227. [Epub ahead of print].
Kobayashi T et al. Int J Hematol. 2014 Nov 11. [Epub ahead of print].
Dimopoulos MA et al. Blood Cancer J. 2014 Nov 7;4:e257. doi: 10.1038/bcj.2014.77